SM

Sofinnova Management VIII, L.L.C.

Momentum followerQuality / disciplined sizingConcentrated strategy

Total reported value

$183.2M

Reporting period: 2017-12-31 · Number of holdings: 8

Sofinnova Management VIII, L.L.C. disclosed 8 holdings in its latest 13F filing for the period ending 2017-12-31, with total reported value of $183.2M and a quarterly turnover rate of 47.6%.

Personality snowflake

Concentration
79.62
Portfolio Stability
47.61
Momentum/Contrarian
100
Sector conviction
0
Diversification
16
Sizing Uniformity
91.77

Recent moves

  • Add 67022C106

    +600.0% $34.9M

  • Trim ONCEEUR

    0.0% -$18.2M

  • Add H5861P103

    +26.7% $15.8M

  • Trim NTRA

    0.0% -$6.0M

  • Trim ACRS

    0.0% -$1.8M

  • Trim 87166L100

    0.0% -$4.0M

Holdings Map

New buyAddUnchangedTrim

Top 10 holdings by weight

Full holdings list this quarter

#TickerIssuerAsset SubclassWeightWeight ChangeShares Change4Q Trend
1Nucana PLC Sponsored AdrStock-Other25.76%+18.29%+600.00%
2Obseva SAStock-Other25.31%+6.70%+26.67%
3ACRSAclaris Therapeutics INCStock-Other20.72%-3.51%
4ONCEEURSpark Therapeutics INCStock-Other13.51%-12.65%
5NTRANatera INCStock-Healthcare7.61%-4.57%
6Auris Med Hldg AGStock-Other2.52%-1.39%
7Histogenics CORPStock-Other2.32%-0.19%
8Synlogic INCStock-Other2.25%-2.68%

Holding changes this quarter

Sofinnova Management VIII, L.L.C.'s most significant position changes for 2017-12-31: Add: Nucana PLC Sponsored Adr — shares +600.00%; Add: Obseva SA — shares +26.67%.

Position changes disclosed by Sofinnova Management VIII, L.L.C. for the quarter ending 2017-12-31, including ticker, issuer, weight change, shares change, and action
#TickerIssuerWeight ChangeShares ChangeAction
1Nucana PLC Sponsored Adr+18.3%+600.00%Add
2Obseva SA+6.7%+26.67%Add
3Histogenics CORP-0.2%Unchanged
4Auris Med Hldg AG-1.4%Unchanged
5Synlogic INC-2.7%Unchanged
6ACRSAclaris Therapeutics INC-3.5%Unchanged
7NTRANatera INC-4.6%Unchanged
8ONCEEURSpark Therapeutics INC-12.7%Unchanged

FAQ

What is Sofinnova Management VIII, L.L.C. and what type of investor is it?
Sofinnova Management VIII, L.L.C. is a investment manager that files SEC Form 13F quarterly, disclosing its U.S. public equity holdings to regulators. As of the most recent reporting period (2017-12-31), the firm manages a tracked equity portfolio valued at approximately $183.2M, spread across 8 disclosed positions.
What are Sofinnova Management VIII, L.L.C.'s largest equity positions?
Based on the latest 13F filing, Sofinnova Management VIII, L.L.C.'s top holdings by market value are: 1. Nucana PLC Sponsored Adr — $47.2M (25.8%) 2. Obseva SA — $46.4M (25.3%) 3. Aclaris Therapeutics INC (ACRS) — $38.0M (20.7%) 4. Spark Therapeutics INC (ONCEEUR) — $24.7M (13.5%) 5. Natera INC (NTRA) — $13.9M (7.6%)
What changes did Sofinnova Management VIII, L.L.C. make in its most recent portfolio filing?
In the latest quarter, Sofinnova Management VIII, L.L.C. was primarily adding exposure — initiating 0 new positions and adding to 2 existing holdings. The largest of these moves: Add: Nucana PLC Sponsored Adr — shares +600.00%; Add: Obseva SA — shares +26.67%
What sectors does Sofinnova Management VIII, L.L.C. focus on?
Sofinnova Management VIII, L.L.C. is concentrated in the following sectors based on its current disclosed equity portfolio: • Health Care: 100.0%